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A significant portion of AML patients have the cytogenetic abnormality t(8;21) which 
generates the fusion protein AML1-ETO, leading to a disruption of the core binding 
factor complex that regulates transcription of hematological genes. Patients harboring the 
translocation alone usually have a good prognosis; however, a substantial portion of 
patients bearing an additional oncogenic receptor tyrosine kinase, KIT, mutation have 
significantly worse prognosis. A mutation of aspartic acid to valine (KITD814V) in the 
activation loop results in altered substrate recognition and utilization, constitutive 
tyrosine autophosphorylation, and promiscuous signaling. Little is known concerning 
possible mechanisms of cooperation between AML1-ETO and KITD814V. Using an IL-
3 dependent murine myeloid cell line, we show that growth of AML1-ETO bearing cells 
remain ligand dependent, while cells that express both AML1-ETO and KITD814V 
demonstrate ligand independent proliferation. Furthermore, functional assays show that 
expression of AML1-ETO and KITD814V leads to an increase in cell cycling and 
decrease in apoptosis that may contribute to the observed ligand independent 
proliferation. Using a syngenic murine transplantation model we demonstrate that mice 
transplanted with AML1-ETO and KITD814V bearing cells succumb to a fatal 
myeloproliferative disease (MPD)-like phenotype, while AML1-ETO expressing mice 
remain disease free. This suggests that AML1-ETO alone is not sufficient to induce 
ligand independent growth, nor MPD, but may cooperate with KITD814V to enhance 
proliferation. Continuing research aims to investigate mechanisms of cooperation 
between KITD814V and AML1-ETO that contribute to ligand independent growth in 
vitro, transformation in vivo, and poor overall prognosis in AML patients bearing the two 
mutations. 
  
 
